Eryptosis in polycythemia vera and essential thrombocythemia*
-
Published:2020-04-03
Issue:
Volume:74
Page:69-76
-
ISSN:0032-5449
-
Container-title:Postępy Higieny i Medycyny Doświadczalnej
-
language:
-
Short-container-title:Postepy Hig Med Dosw
Author:
Kopka Paweł1, Bliźniewska Katarzyna1, Sicińska Paulina2, Duchnowicz Piotr2, Bukowska Bożena2, Treliński Jacek1, Chojnowski Krzysztof1
Affiliation:
1. Department of Hemostasis Disorders, Medical University of Lodz, Department of Hematology, Copernicus Memorial Hospital, Lodz, Poland 2. Department of Environmental Pollution Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
Abstract
Aim: Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia–negative myeloproliferative neoplasms with documented apoptosis impairment at the level of hematopoietic stem cell. However, so far no study has evaluated apoptosis of circulating blood neoplastic cells, including the suicidal death of erythrocytes – eryptosis.
Material/Methods: Erythrocytes from 61 patients (24 PV and 37 ET) naïve to and treated with hydroxyurea (HU) and 13 healthy individuals were analysed using flow cytometry to quantify phosphatidylserine (PS) externalization from Annexin-V-binding, calpain activity from 7-amino-4-chloromethylcoumarin (CMAC)-fluorescence, cell volume from forward scattered light (FSC) and cell shape from side scattered light (SSC).
Results: Significantly increased levels of calpain activity and PS exposure were observed in both ET and PV naïve patients, indicating enhanced eryptosis. Among HU-treated patients, a significant increase in calpain activity in the ET group and a decrease in the PV group were observed compared to patients without cytoreductive therapy. Among PV patients, FSC was substantially higher in the HU-treated group than in the naïve group, whereas no significant differences were found between HU-treated and HU-naïve groups of ET patients.
Conclusions: The enhanced eryptosis in ET and PV patients may be a form of systemic compensation of the pathological bone marrow overproduction of erythrocytes. HU, the basic cytoreductive drug used in ET and PV, may affect eryptosis in PV and ET in different ways depending on disease. The JAK2V617F mutation was not observed to have any effect on eryptosis in ET.
Publisher
Walter de Gruyter GmbH
Subject
Infectious Diseases,Microbiology (medical)
Reference34 articles.
1. Berlin N.I., Lawrence J.H., Lee H.C.: The life span of the red bloodcell in chronic leukemia and polycythemia. Science, 1951; 114:385–387 2. Berlin N.I., Reynafarcje C., Lawrence J.H.: Red cell life span inthe polycythemia of high altitude. J. Appl. Physiol., 1954; 7: 271–272 3. Bosman G.J., Willekens F.L., Werre J.M.: Erythrocyte aging: a morethan superficial resemblance to apoptosis? Cell Physiol. Biochem.,2005; 16: 1–8 4. Bratosin D., Estaquier J., Petit F., Arnoult D., Quatannens B., TissierJ.P., Slomianny C., Sartiaux C., Alonso C., Huart J.J., Montreuil J., AmeisenJ.C.: Programmed cell death in mature erythrocytes: a modelfor investigating death effector pathways operating in the absenceof mitochondria. Cell Death Differ., 2001; 8: 1143–1156 5. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., MarsdenJ.T., Duffy A., Boyd E.M., Bench A.J., Scott M.A., Vassiliou G.S., MilliganD.W., Smith S.R., Erber W.N., Bareford D., Wilkins B.S., et al.:Definition of subtypes of essential thrombocythaemia and relationto polycythaemiavera based on JAK2 V617F mutation status: a prospectivestudy. Lancet, 2005; 366: 1945–1953
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|